Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9963459 | 0.84 | EPHX1 (0.40) | EPHX1HPGDL3MBTL1KDM4EPKM | |
| SCHEMBL27264586 | 0.83 | PIK3CD (0.34) | EPHX1ALDH1A1TSHRSMN1; SMN2PIK3CD | |
| SCHEMBL13164473 | 0.82 | ALDH1A1 (0.53) | EPHX1ALDH1A1TSHRPIK3CD | |
| SCHEMBL9966002 | 0.82 | EPHX1 (0.39) | EPHX1HPGDL3MBTL1KDM4EPKM | |
| SCHEMBL19392024 | 0.82 | EPHX1 (0.39) | EPHX1HPGDL3MBTL1KDM4EPKM | |
| SCHEMBL23964744 | 0.82 | EPHX1 (0.39) | EPHX1HPGDL3MBTL1KDM4EPKM | |
| SCHEMBL8621951 | 0.81 | ATM (0.36) | PIK3CD | |
| SCHEMBL21030685 | 0.80 | HPGD (0.41) | EPHX1HPGDL3MBTL1KDM4EPKM | |
| SCHEMBL9891903 | 0.79 | POLB (0.44) | EPHX1HPGDTP53KMT2AALDH1A1 | |
| SCHEMBL14104999 | 0.79 | MMP8 (0.35) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190606-A1 | SULFATE FREE PERSONAL CLEANSING COMPOSITION COMPRISING EFFECTIVE PRESERVATION | THE PROCTER & GAMBLE COMPANY | 2023-06-22 | — | — | US | disclosed |
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| WO-2021112213-A1 | 2,4-DIOXO-1,4-DIHYDROTHIENOPYRIMIDINE COMPOUND, AGRICULTURAL OR HORTICULTURAL FUNGICIDAL AGENT, OR MEDICAL/ANIMAL ANTIFUNGAL AGENT, CONTAINING THIS | 日本曹達株式会社 | 2021-06-10 | — | — | WO | disclosed |
| US-10912719-B2 | Personal care composition and method of making | THE PROCTER AND GAMBLE COMPANY (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200316032-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING RETINAL PIGMENT EPITHELIUM DEGENERATION AND METHODS USING THE SAME | THE SCHEPENS EYE RESEARCH, INSTITUTE, INC. | 2020-10-08 | — | — | US | disclosed |
| US-10550073-B2 | Benzamide derivative | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2020-02-04 | — | — | US | disclosed |
| EP-2470215-B1 | BISPHOSPHONATE-PRODRUGS | VERGELL MEDICAL S A (CH) | 2018-04-25 | — | — | EP | disclosed |
| US-20170252273-A1 | AEROSOL ANTIDANDRUFF COMPOSITION | THE PROCTER & GAMBLE COMPANY | 2017-09-07 | — | — | US | disclosed |
| US-9732344-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170216271-A1 | SALTS OF HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-08-03 | — | — | US | disclosed |
| US-8343993-B2 | Hydroxyalkyl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343993-B2 | Hydroxyalkyl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-8158794-B2 | Hydroxyalkyl substituted imidazoquinoline compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158794-B2 | Hydroxyalkyl substituted imidazoquinoline compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090253695-A1 | Hydroxyalkyl Substituted Imidazonaphthyridines | COLEY PHARMACEUTICAL GROUP, INC, (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253695-A1 | Hydroxyalkyl Substituted Imidazonaphthyridines | COLEY PHARMACEUTICAL GROUP, INC, (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090069314-A1 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069314-A1 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190606-A1 | SULFATE FREE PERSONAL CLEANSING COMPOSITION COMPRISING EFFECTIVE PRESERVATION | PRSS3, PLP2, PRSS2 | EPHX1 3968/4885HPGD 2252/4885L3MBTL1 3921/4885 |
| US-10912719-B2 | Personal care composition and method of making | CUTA, POLR1C, KRT18 | EPHX1 3361/4885HPGD 2280/4885L3MBTL1 2463/4885 |
| US-20170252273-A1 | AEROSOL ANTIDANDRUFF COMPOSITION | ANXA1, ANXA11, POLR1C | EPHX1 4753/4885HPGD 3414/4885L3MBTL1 4131/4885 |
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | EPHX1 3770/4885HPGD 4329/4885L3MBTL1 137/4885 |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | IFNG, IFNAR1, EIF2AK2 | EPHX1 1109/4885HPGD 58/4885L3MBTL1 2979/4885 |
| US-20090253695-A1 | Hydroxyalkyl Substituted Imidazonaphthyridines | IFNG, IFNAR1, IRF3 | EPHX1 1351/4885HPGD 172/4885L3MBTL1 2355/4885 |
| US-20170216271-A1 | SALTS OF HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, VHL, HIF1A | EPHX1 2563/4885HPGD 42/4885L3MBTL1 2283/4885 |
| US-20200316032-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING RETINAL PIGMENT EPITHELIUM DEGENERATION AND METHODS USING THE SAME | ALDH1A2, RBP4, RBP1 | EPHX1 3355/4885HPGD 217/4885L3MBTL1 4072/4885 |
| US-20090069314-A1 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods | IFNG, IRF3, IFNAR1 | EPHX1 569/4885HPGD 294/4885L3MBTL1 2691/4885 |
| US-10550073-B2 | Benzamide derivative | CYP3A5, ABCB1, CYP2D6 | EPHX1 1725/4885HPGD 1168/4885L3MBTL1 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.